Agreement between Kamada and Baxter

24 August 2010:

Kamada enters into an exclusive distribution and manufacturing agreement with Baxter International for Kamada’s treatment of Alpha-1 antitrypsin Deficiency, the inhaled product called Glassia. Kamada will receive staged payments of $45m including an upfront payment of $20m; Kamada will also be eligible to receive up to $25m in aggregate payments upon the achievement of milestones and royalty payments on net sales of the product produced by Baxter.